摘要
本文应用HBAg-iRNA穴位注射(穴注)与肝必复口服治疗慢性乙型肝炎(慢乙肝)100例，治前HBsAg、HBeAg、抗-HBc均阳性，抗-HBs、抗-HBc均阴性，多数SGPT异常，三个月为一疗程，疗程结束及治后一年复查上述指标。结果显示两组近期疗效分别为：HBeAg转阴50％，18%，抗-HBe转阳46％，18％，HBsAg滴度显降48％、16％，抗-HBc下降32％，2％，临床症状体征改善90％、36％，均以HBAg-iRNA为佳(P<0．05)；远期疗效分别为：HBeAg转阴52％、14．63%，抗-HBe转阳48%，14．63％，HBsAg转阴或显降为72％、14．63%，抗-HBs转阳6％，0％，抗-HBc转阴12%、0％，SGPT恢复正常82％．58．54％，亦以HBAg-iRNA为优(P<0．05)。
This paper reports 100 cases of chronic hepatitis B treated with pointinjection of HBAg-iRNA and oral administration of GanBiFu. Before thetreatment, serological indexes of HBsAg, HBeAg and anti-HBc were all positive;anti-HBs, anti-HBe, negative; and SGPT abnormal in most of the patients. We made3 months as one course of treatment. Then the indexes above were observed atthe end of each course and one year after the treatment. The results are asfollows: the short term therapeutic effective rates in group 1 and group 2 are50% and 18% respectively in the transfer of HBeAg to negative; 46% and 18%n the transfer of anti-HBe to positive; 48% and 16% in the significant dropif HBsAg titer; and 32% and 2% in the drop of anti-HBc. The improvementoate of clinical symptoms are 90% and 36% especially with HBAg-iRNA (P<r0.05) in the two groups. The long term therapeutic effective rates in groups 1and group 2 are 52% and 14.63% respectively in the transfer of HBeAg tonegative; 48% and 14.63% in the transfer of anti-HBe to positive; 72% and14.63% in the transfer of HBsAg to positive with a significant drop of its titer;6% and 0% in the transfer of anti-HBs to positive; 12% and 0% in the transferof anti-HBc to negative; and 82% and 58.54% in the recovery of SGPT.HBAg-iRNA also shows better rates in the long-term therapeutic effect thanGanBiFu (P<0.05).
出处
《南通医学院学报》
1989年第2期98-100,158,共3页
ACTA Academiae Medicinae Nantong
